Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic™ as efficacious as nebulized budesonide in adult asthmatics?  by O'Reilly, J.F. et al.
RESPIRATORY MEDICINE (1998) 92, 111-117 
Is high-dose fluticasone propionate via a 
metered-dose inhaler and Volumatic a as efficacious 
as nebulized budesonide in adult asthmatics? 
J. F. O’REILLY”, D. C. WEIR+, S. BANHAM*, G. S. BASRAN’, G. BOYDa AND 
K. R. PATELI’ 
“Blackpool Victoria Hospital, UK..; ‘North Manchester General Hospital, U.K. 
*Glasgow Royal Infivmavy, U.K.; ‘Rothevham District General Hospital, U.K. 
~Stobhill General Hospital, Glasgow, U.K.; “Western Infirmary, Glasgow, U.K. 
The efficacy and tolerability of fluticasone propionate (FP) 2 mg daily via a metered-dose inhaler and Volumatic@ 
(GlaxoWellcome) spacer device was compared with nebulized budesonide (nBUD), 2 and 4 mg daily, in a 
multi-centre, open-label, cross-over study of adult asthmatics. Patients received, in random order, either 4 weeks of 
treatment with FP followed by 4 weeks of treatment with nBUD, or vice versa, with an intervening 4 week ‘wash-out’ 
period between treatments. Thirty patients completed the study, of whom 24 were evaluable. In terms of the primary 
efficacy parameter, change in mean morning peak expiratory flow (PEF) (1 min - ‘) from baseline to the fourth week 
of each treatment period, FP was more effective than nBUD [mean difference (FP - nBUD) 21.1 1 min ~ I, P=O.O07, 
95% CI (6.5, 35.7)]. Sub-group analysis demonstrated FP to be superior to the 4 mg nBUD [mean treatment 
difference (FP - nBUD) 42.9 1 min ~ ‘, P=O.O26, 95% CI (7.1, 78,8)] and at least as efficacious as the 2 mg nBUD 
sub-group [mean treatment difference (FP - nBUD) 10.2 1 min - ‘, P=O.211, 95% CI ( - 6.5, 26.9)]. Furthermore, 
larger reductions in diurnal variation were observed during FP treatment [mean treatment difference (FP - nBUD) 
- 4.4 percentage points, P=O.O28, 95% CI (- 8.4, - 0.5)]. There was no significant difference between the 
treatments for the proportion of symptom-free 24 h periods. Of those expressing a preference, significantly more 
patients found FP via a metered-dose inhaler and spacer device both easier to administer (78%, P=O.O07) and more 
convenient to take (76%, P=O.OOS) than nebulized budesonide. In addition, cost per patient analysis showed that 
nebulized budesonide was from 1.7 to 3.5 times more expensive than FP. 
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Introduction 
Nebulized budesonide (nBUD) is the only nebulized 
corticosteroid currently available in the U.K., and is 
licensed at a higher dose than either the aerosol or dry 
powder formulations of budesonide. It is used by a minority 
of severe asthmatics whose disease is difficult to control. 
There is some evidence to suggest its use may reduce the 
need for oral steroids (1,2). 
However, this mode of delivery suffers the disadvantages 
of inconvenience and portability. In addition, several 
studies have demonstrated a wide variation between differ- 
ent compressor/nebulizer combinations in the flow rate and 
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particle size produced, which is a major determinant of the 
amount of drug made available to the lungs (3-5). To date, 
there have been no studies comparing the efficacy of 
high-dose inhaled corticosteroids when delivered via a 
nebulizer or the more commonly used and convenient 
metered-dose inhaler (MDI) and spacer device. Fluticasone 
propionate (FP) is the most recently introduced inhaled 
corticosteroid available for the treatment of asthma. 
Studies using MDIs and powder inhalers comparing FP 
with both budesonide and beclomethasone dipropionate 
have shown, over a range of doses, that FP is as efficacious 
as the older corticosteroids, when administered at half the 
microgram dose (6-12). FP is licensed for use in adults up 
to a dose of 2 mg daily, thus enabling patients to receive 
what is, in effect, a higher dose of inhaled corticosteroid via 
the more commonly used delivery devices, than was 
possible previously (13). 
This study aimed to compare the efficacy and tolerability 
of inhaled FP 2 mg daily via an MD1 and Volumatic? 
(GlaxoWellcome) spacer device with nBUD (2 and 4 mg 
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Entry Randomization Wash-out Cross-over Final visit 
Visit 1 2 3 4 5 
A A 
t 
A A 
1 week run-in 
period 
Asthma therapies taken as during run-in period 
(including usual dose of nBUD) 
FP 2 mg day-l 
(instead of usual 
dose of nBUD) 
4 weeks 
TPI 
4 weeks 
(Wash-out) 
4 weeks 
TP II 
All pre-study 
asthma therapies 
continued 
(including usual 
dose of nBUD) 
FP 2 mg day-’ 
(instead of usual 
dose of nBUD) 
Asthma therapies taken as during run-in period 
(including usual dose of nBUD) 
v v v 1 7 
Visit 1 2 3 4 5 
FIG. 1. Study plan. TP, treatment period; FP, fluticasone propionate via a metered-dose inhaler and Volumatic@ 
spacer device; nBUD, nebulized budesonide. Notes: 1. During FP treatment, only nBUD was stopped; all other 
asthma therapies as taken during the run-in period were continued. 2. The patient’s usual dose of nBUD was either 
2 or 4 mg daily. 
daily), to determine whether FP can provide an alternative The study was approved by an ethics committee local to 
to regular nBUD therapy, in those patients already using each participating centre, and written informed consent was 
nBUD as part of their maintenance regimen. obtained from each patient prior to entry. 
Patients and Methods 
PATIENTS 
Patients aged 18-70 years inclusive were eligible to enter the 
study if they had documented evidence of long-term 
asthma, demonstrating a typical clinical pattern of marked 
variability in symptoms and significant (> 15%) vari- 
ability and reversibility of peak expiratory flow (PEF) to 
bronchodilators, and/or PEF variability. Patients had to 
have been using nBUD regularly, and for the 4 weeks 
immediately preceding the study, at a daily dose of either 2 
or 4 mg. Patients were also required to be using their 
nebulizer for regular bronchodilator therapy at entry and 
over the preceding 4 weeks. Patients were excluded if they 
were taking any other inhaled corticosteroid by any other 
device, or had done so during the preceding 4 weeks, or had 
suffered an exacerbation of their asthma requiring hospital- 
ization during this period. Current regular smokers (defined 
as greater than five cigarettes per day) were also excluded. 
Patients were allowed to be on maintenance oral cortico- 
steroids, but the dose had to remain constant for them to be 
included in the efficacy analysis. 
STUDY DESIGN 
This was a multi-centre, open-label, randomized cross-over 
trial conducted in 10 hospital and General Practice centres. 
A summary of the study plan is shown in Fig. 1. After a 1 
week run-in period, during which patients took their usual 
asthma medication, including their usual dose of nBUD (2 
or 4 mg daily), patients were randomized to Treatment 
Period 1. One group received FP 1 mg b.i.d. via a MD1 and 
Volumatic@ spacer device instead of their usual nBUD 
(continuing all other asthma therapies), whilst the second 
group continued to receive all their usual asthma therapies, 
including their usual dose of nBUD. After 4 weeks, all 
patients then entered the wash-out period during which 
they took the same asthma medications as during the 
run-in, for a further 4 weeks. The two groups then crossed 
over such that the first group received their usual dose of 
nBUD whilst the second group received FP instead of 
nBUD, for the final 4 weeks of the study (Treatment Period 
2). Patients were allowed to extend the wash-out period, by 
a maximum of 4 weeks, if they had altered any of their 
asthma medications, and could continue in the study pro- 
vided that their asthma medications in the 4 weeks imme- 
diately preceding Treatment Period 2 were the same as 
during the run-in period. 
Withdrawal was at the discretion of the physician or at 
the request of the patient. 
ASSESSMENTS 
During the run-in, wash-out and treatment period, patients 
kept a daily record of their morning and evening PEF rates, 
daytime and night-time symptom scores and whether 
or not they had symptoms on waking. At the end of the 
study, patients were asked which of the two treatments 
they preferred. Adverse events 
inclusive. 
were recorded at visits 225 
STATISTICAL METHODS 
Efficacy and Device Handling 
The primary efficacy parameter was changed from baseline 
(or wash-out for Treatment Period 2) in mean morning 
PEF. Based on at least 90% power to demonstrate FP 2 mg 
daily was at least as effective as nBUD (2 or 4mg daily) 
with 95% confidence intervals, a maximum acceptable 
clinical difference of 15 1 min ~ r in favour of budesonide, 
and assuming a residual standard deviation of 25 1 min ~ i 
from analysis of covariance (ANCOVA), it was calculated 
that 15 evaluable patients would be required in each 
sequence group, a total of 30 patients. 
The primary efficacy parameter and the two secondary 
efficacy parameters, daily diurnal variation and proportion 
of symptom-free days, were analysed using the efficacy 
sample of patients. This sample included all randomized 
patients who completed at least 4 weeks of each treatment 
period, and who did not take additional oral steroid 
medication for the treatment of an asthma exacerbation 
during the treatment periods. Daily diurnal variation (DV) 
was calculated based on the following formula: 
DV%= 100 x 
(maximum - minimum) 
maximum 
(of the morning and previous evening PEF) 
For each patient, the mean morning PEF (1 min - ‘), the 
mean daily diurnal variation (%), and the proportion 
of symptom-free 24-h days were calculated over the last 
7 days of each study period. In addition, each patients’ 
changes from baseline were also calculated for all of these 
parameters. ANCOVA, appropriate for a cross-over design 
(14), was used to compare the two treatments in change 
from baseline in mean morning PEF and diurnal variation. 
The stratification variable, total daily dose of nBUD (2 or 
4 mg) at study entry, was included as a covariate in the 
model. Due to evidence of a treatment difference which 
varied according to nBUD dose for change from baseline in 
mean morning PEF, additional treatment comparisons 
for this parameter were carried out for each of the two 
dose strata subgroups (2 and 4 mg) separately. No other 
parameters were affected significantly by this interaction. 
The statistical comparison of the changes in symptom-free 
24-h days was performed using the permutation test, using 
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the actual change from baseline data as the scores. Device 
preference data were analysed using the Mainland-Gart test 
for all patients who completed both treatment periods. 
All statistical tests were two-sided, and the significance 
level was taken as 5%. For all efficacy analyses, the baseline 
and wash-out values were incorporated into the test for 
carry-over and treatment by period interaction effects. 
Statistical analysis was carried out using PC SAS version 
6.08 and StatXact Turbo version 2.11. 
Cost Analysis 
The total number of days that study medication was used 
during the two study treatment periods was determined for 
each patient, and this was multiplied by the daily cost of the 
medication, calculated from the unit cost as defined in the 
British National Formulary (September 1995 edition). For 
nBUD, the cost was based on 500,~~g ml- ’ Pulmicort 
Respules@ (Astra) in a 20 x 2 ml unit pack (L44.64) and 
for FP, the costs were based on 250pg doses in a 120-dose 
Flixotide@ (GlaxoWellcome) (E38.86). Patient costs for FP 
and nBUD were totalled separately for the patients on 2 
and 4 mg nBUD. These total costs were then divided by the 
number of patients to provide a cost per patient for each 
drug. The relative costs of FP compared with nBUD 2 and 
4 mg doses, were also calculated. 
Results 
STUDY POPULATION 
Thirty-seven patients were randomized to the study in total 
(the intention to treat sample), 19 to sequence Group A (FP 
1 mg b.i.d. followed by nBUD) and 18 to sequence Group B 
(nBUD followed by FP 1 mg b.i.d.). Seven patients with- 
drew after randomization, six of whom withdrew due to 
adverse events. The seventh patient asked to be withdrawn 
after completing the first treatment period on FP as she 
wished to continue on this treatment due to improved 
asthma control. Five of the adverse events reported were 
asthma exacerbations (four occurred in the wash-out period 
and one in Treatment Period 2 whilst on FP) and the sixth 
was a headache (FP; Treatment Period 2). Of the 30 
patients completing the study, a further six were excluded 
from the analysis; three took extra medication for a de- 
terioration in their asthma control (all whilst on nBUD, one 
during Treatment Period 1 and two during Treatment 
Period 2), one patient reduced the dose of oral cortico- 
steroids (for arthritis), and for two patients, no diary data 
were available. Thus, 24 patients were included in the 
efficacy analysis, 12 in each sequence group. Of these 24 
patients, 16 were taking 2mg daily and eight were taking 
4 mg daily. The demographics and asthma history of the 
efficacy sample, by sequence group, are shown in Table 1. 
Asthma history is also shown by nBUD dose, together with 
concurrent asthma medications, in Table 2. Values for the 
lung function parameters at the baseline of each treatment 
period are shown for the efficacy sample in Table 3. These 
data show that the baseline mean morning PEF was similar 
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TABLE 1. Demography and asthma history - efficacy sample 
Sequence Group A Sequence Group B 
(FP-tnBUD) (nBUD+FP) 
(n= 12) (n= 12) 
Sex 
Females 5 (42%) 
Males I (58%) 
Age (years) 
Mean (SD) 51.5 (9.4) 
Range 28.0-63.0 
Duration of asthma (years) 
Mean (SD) 25.4 (16.3) 
Range 1.5-53.0 
6 (50%) 
6 (50%) 
50.2 (13.0) 
28.0-67.0 
26.3 (15.9) 
6.0-53.0 
TABLE 2. Asthma duration and concurrent asthma medica- 
tions at entry by nebulized budesonide dose-efficacy 
sample 
2 mg nBUD 4 mg nBUD 
(n= 16) (n = 8) 
Asthma medications 
No. of patients (%) 
Salbutamol 10 (62.5) 
Terbutaline 8 (50.0) 
Anti-cholinergics 14 (87.5) 
Xanthines 10 (62.5) 
Salmeterol 6 (37.5) 
Cromoglycate 1 (6.3) 
Prednisolone 5 (31.3) 
Methotrexate 1 (6.3) 
Duration of asthma (years) 
Mean (SD) 26.9 (15.60) 
6 (75.0) 
4 (50.0) 
7 (87.5) 
4 (50.0) 
3 (37.5) 
0 (0.0) 
4 (50.0) 
1 (12.5) 
23.9 (17.1) 
before both study treatments, and not significantly different 
between the two nBUD dose groups. The baseline mean 
diurnal variation was also similar before both treatments, 
55 - 
50 - 
45 ~ 
dr‘ 40- 
.5 35- 
52.0 
1 
P = 0.026 
9.1 10 - P = 0.21 P 6.3 = 0.007 
5- 
0 
-r; 
”  
All patients 2 mg nBUD 
(n =24) (n = 16) 
"y",:" 
n 
FIG. 2. Mean change from baseline in patient’s mean 
morning peak expiratory flow (PEF) (1 min ~ ‘) - efficacy 
sample. Open bars, FP; solid bars, nBUD. 
but was lower in the 4 mg nBUD patients than in the 2 mg 
nBUD patients. 
PRIMARY EFFICACY PARAMETER 
The mean change from baseline in mean morning PEF are 
shown in Fig. 2. Overall, whilst there was little mean change 
observed during treatment with nBUD, improvements were 
observed during treatment with FP. Eight patients did 
improve more whilst receiving 2 mg nBUD compared with 
FP. All these patients were on different nebulizer/ 
compressor combinations, and so this improvement cannot 
be attributed to a particular type of equipment. 
The mean and 95% confidence intervals for the treatment 
difference (FP-nBUD) in change from baseline in mean 
morning PEF are shown in Fig. 3, with individual patient 
data plotted alongside. Overall, the mean treatment 
difference was 21.1 1 min -I in favour of FP which was 
statistically significant (P=O.O07). for the 2 mg nBUD 
sub-group, the treatment difference was 10.2 1 min - ’ 
(P=O.21), and for the 4 mg nBUD sub- group, 42.9 1 min- ’ 
(P=O.O26). These data show that overall and in the 4 mg 
TABLE 3. Summary of lung function at the baseline for each treatment period - efficacy sample 
All 
(n=24) 
Pre-FP 
2mg 
nBUD 
(n= 16) 
4mg 
nBUD 
(n=8) 
All 
(n=24) 
Pre-nBUD 
2mg 
nBUD 
(n= 16) 
4w 
nBUD 
(n=X) 
Mean morning PEF (1 min ~ ‘) 
Mean 266.0 269.2 259.7 264.2 262.6 267.4 
6”) (73.1) (71.1) (81.6) (67.5) (60.1) (848) 
DV (%) 
Mean 12.9 14.1 10.5 12.4 13.7 9.8 
6”) (9.4) (9.9) (8.5) (7.8) (8.1) (7.1) 
2 mg nBUD 
(n = 16) 
E 
78.8 
4 mg nBUD 
(n = 8) 
FIG. 3. Individual patient data, mean and 95% confidence 
intervals for the estimated true treatment difference 
(FP-nBUD) in change from baseline in mean morning 
PEF (1 min - ‘) - efficacy sample. 
TABLE 4. Mean change from baseline in patients’ diurnal 
variation (percentage points) - efficacy sample 
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nBUD sub-group, FP was more efficacious than nBUD in 
terms of mean morning PEF. Within the 2 mg nBUD 
sub-group, it can be stated that FP was at least efficacious 
as nBUD, since the confidence interval did not extend 
beyond 15 1 min - i in favour of nBUD. 
SECONDARY EFFICACY PARAMETERS 
Diwnal Variation 
The change from baseline in diurnal variation is shown 
in Table 4 The adjusted mean treatment difference 
(FB-nBUD) was - 4.4 percentage points (p.p) (P=O.O28, 
95% CI [ - 8.4, - 0.5). Thus, FP was statistically signifi- 
cantly better at reducing diurnal variation than nBUD. 
Although the treatment difference was greater in the 2 mg 
nBUD patients than in the 4 mg nBUD patients ( - 5.9 p.p. 
vs - 1.9 p.p.), there was no significance dose by treatment 
interaction, and thus no sub-group analyses were carried 
out for this parameter. 
Change from 
baseline in DV (p.p) 
After FP After nBUD 
treatment treatment 
All (n=24) - 3.4 1.1 
2 mg nBUD sub-group (n= 16) - 4.4 1.5 
4 mg nBUD sub-group (7~ = 8) - 1.4 0.5 
Symptom-free 24-h Periods 
During the pre-FP and nBUD baseline periods, the ma- 
jority of patients (75% and 79% of patients, respectively) 
had no symptom-free days. After FP and nBUD treatment 
67% and 87% of patients, respectively, did not experience 
any change in their symptom scores, 25% and 13% showed 
an improvement, and 8% and 0% worsened. The difference 
between treatments was not statistically significant 
(P=O.41). 
100, 
80 I 
90 
h 
70 1 
8 
S 60~ 
x 
% 50 - B 
J 
8 40- 
5 
pI 30- 
78 
76 
f '= 0.008 
24 I 
1 __ 
P = 0.11 
34 1 
Easier to administer 
(n = 27) 
[No preference = 
three patients] 
More convenient to use 
(n = 29) 
[No preference = 
one patient] 
Overall preference 
(n = 29) 
[No preference = 
one patient] 
FIG. 4. Percentage of patients preferring each treatment for three treatment preference questions ~ all patients who com- 
pleted the study (n=30). For FP and BUD, the percentages were calculated of those patients who expressed a preference. 
Open bars, FP; solid bars, nBUD. 
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TABLE 5. Cost analysis 
Treatment 
Type of medication 
Fluticasone 
propionate 
(n=24) 
Nebulized budesonide 
2mg (n=16) 4 mg (n=8) 
Medication used during study 
Costs per patient 
Relative cost ratio per patient (nBUD/FP) 
&II.51 E134.36 E272.06 
1.7 3.5 
Treatment Preference 
The responses to the device preference questions are 
shown in Fig. 4. These data show strong evidence that 
patients considered FP via the MD1 and Volumatic@ both 
easier to administer (P=O,OO7) and more convenient to 
use (P=O.OOS). Of those patients who expressed an 
overall preference, 66% preferred FP via the MD1 and 
Volumatic@, compared to 34% who preferred nBUD, 
although this difference was not statistically significant 
(P=O.ll). 
and the kinetics of delivery of a drug in suspension. This 
study targeted the minority of severe asthmatics for whom 
regular nBUD appears to offer some benefit in maintaining 
asthma control, and tested whether FP 2mg daily via 
an MD1 and Volumatic@ was clinically as effective in 
maintaining this level of control if substituted for nBUD. 
Cost Analysis 
The asthma-related medication costs excluding study drug 
were similar during the FP and nBUD treatment periods, 
and between the two nBUD dose groups (around &50 per 
patient). The study drug castings are shown in Table 5. 
These show that the nBUD cost more than the FP. 
To conform with current clinical practice, patients used 
their own nebulizers and compressors throughout the 
study. No attempt was made to standardize equipment or 
alter the usual maintenance checks undertaken by the 
patients. Previous studies have shown that different 
nebulizerlcompressor combinations have different perform- 
ances in terms of the flow rate produced at the nebulizer 
and the particle size profiles produced (335). Any variation 
in performance will have a direct effect on the amount of 
drug available to the lung, and therefore the actual dose the 
patient receives. For this reason, it was not the intention of 
this study to examine dose response, even though patients 
were nominally using two different doses of nBUD. A 
dose-response study would have required standardization 
of the delivery system. 
SAFETY 
There were four serious adverse events reported by three 
patients, all of which occurred during the wash-out period 
when patients were receiving nBUD. Three of these were 
exacerbations of asthma which led to all three patients 
being hospitalized (two who had received FP in the first 
treatment period and one who had received nBUD pre- 
viously). The fourth event was a lower respiratory tract 
infection. All resolved and were considered unlikely to be 
related or were not related to treatment. 
Twelve patients reported a total of 21 minor adverse 
events whilst receiving FP, and 11 patients reported a total 
of 17 events during the nBUD treatment arm. The majority 
of these events were related to the lower respiratory tract 
and asthma. 
In terms of the change in mean morning PEF, the 
primary parameter, FP was shown to be more efficacious 
than nBUD. The statistical analysis showed, however, that 
this treatment difference was affected by the dose of nBUD. 
A sub-group analysis showed, somewhat surprisingly, that 
the treatment difference in favour of FP was greater in 
patients who had received 4 mg nBUD than those who 
received 2 mg nBUD. Thus, FP was at least as efficacious as 
nBUD in the 2 mg sub-group, and significantly better in the 
4 mg sub-group. It should, however, be noted that there 
were only eight patients in the nBUD 4 mg sub-group. The 
confidence interval in this group was very wide for this 
reason, and because of the wide variation in response. 
Discussion 
The response in diurnal variation was not consistent with 
that seen for the change in mean morning PEF, as a greater 
improvement was seen in the 2 mg nBUD sub-group com- 
pared with the 4 mg nBUD sub-group, although it could be 
argued that the 2 mg nBUD sub-group had more room for 
improvement due to the higher baseline diurnal variation in 
this group. 
Nebulized budesonide is not generally introduced for There are several factors which need to be considered 
the treatment of asthma until other delivery methods and when interpreting these results. There were at least 17 
drugs have failed to keep the patient’s condition under different combinations of compressor and nebulizer used 
satisfactory control. It is an expensive and relatively com- which could give rise to a large variability in the actual dose 
plex form of therapy, both in terms of necessary equipment of budesonide which the patients received to the lung. The 
effect of different fill volumes is also unclear. The longer 
inhalation time may have allowed more evaporation to 
occur at the higher dose, which could increase the viscosity 
of the suspension and possibly reduce the proportion 
of drug delivered to the lung. Individual responsiveness 
to fluticasone may be independent of responsiveness to 
budesonide. There may have been a difference in com- 
pliance between the two dose groups as patients in the 
higher budesonide dose group were required to take two 
ampoules twice a day compared to the one ampoule twice 
daily in the 2 mg group. However, compliance was not 
assessed formally in this study and indeed is extremely 
difficult to assess in clinical practice. 
Patient preference for a particular drug and device com- 
bination is another aspect of management which is likely to 
affect compliance. In this study, the aim was to compare the 
patient’s current nBUD regimen with the replacement of 
budesonide by FP. Patients did not discontinue nebulizer 
use during FP treatment since they continued nebulized 
bronchodilator therapy. Despite use of the MD1 and 
Volumatic@ as an additional device, more than three times 
as many patients found it easier and more convenient to 
administer FP by this route, than budesonide by nebuliz- 
ation. Although almost twice as many patients preferred 
FP via the MD1 and Volumati@ to nBUD overall, this 
difference did not reach statistical significance. This was a 
more general and subjective question, and it is possible 
that patients took into consideration any previous 
beneficial experience of a nebulizer and may thus have had 
a pre-conception of benefit from this device. 
Cost, as well as additional benefit, of a new treatment or 
regimen must be taken into consideration before it can be 
proposed as a viable alternative to a current treatment. On 
a per patient cost basis, the 2 mg nBUD used during the 
study treatment period was 1.7 times more expensive than 
the FP treatment, and for 4 mg nBUD this ratio increased 
to 3.5. This differential would be even larger if the cost of 
the nebulizer equipment and maintenance were taken into 
consideration. 
In conclusion, FP 2 mg daily via the MD1 and 
Volumatic@ has been shown to be at least as efficacious as, 
and less expensive than, either 2 or 4 mg daily nBUD. 
Fluticasone propionate via the MD1 and Volumatic@ may; 
therefore, offer an alternative to nBUD in those patients 
who have been deemed to require such therapy, with 
the advantages of being cheaper, simpler and in a more 
standardized form of delivery than nBUD. 
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